Abstract
Twenty-five patients with disseminated gastrointestinal malignancies were treated in a phase I study with a combination of ftorafur and mitomycin C or florafur and methyl-CCNU. Most patients had been heavily treated previously. Gastrointestinal, central nervous system, and marrow toxicity were manageable. Tumor regression was noted in five of 25 patients. A large-scale phase II study in untreated patients with gastrointestinal malignancies appears indicated with a combination of these agents.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Bone Marrow / drug effects
-
Drug Evaluation
-
Drug Therapy, Combination
-
Fluorouracil / analogs & derivatives*
-
Gastrointestinal Neoplasms / drug therapy*
-
Humans
-
Hypotension, Orthostatic / chemically induced
-
Mitomycins / adverse effects
-
Mitomycins / therapeutic use*
-
Nitrosourea Compounds / therapeutic use*
-
Remission, Spontaneous
-
Semustine / adverse effects
-
Semustine / therapeutic use*
-
Tegafur / adverse effects
-
Tegafur / therapeutic use*
Substances
-
Mitomycins
-
Nitrosourea Compounds
-
Semustine
-
Tegafur
-
Fluorouracil